Evidence map›Paper›PMID 32001482›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2020

Exploiting TCR Recognition of Shared Hotspot Oncogene-encoded Neoantigens.

Irene Olivera, Iñaki Etxeberria, Elixabet Bolaños, María Gato-Cañas, Ignacio Melero

Abstract readComment
PubMed Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 58% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Regional and intratumoral adoptive T-cell therapy.Immuno-oncology technology · 2024
    Review
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 1 institution in 2 countries.

Irene OliveraProgram of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.
Iñaki EtxeberriaProgram of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.ORCID 0000-0003-2713-0836
Elixabet BolañosProgram of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.
María Gato-CañasProgram of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.
Ignacio MeleroProgram of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain. imelero@unav.es.
Navarre Institute of Health Research · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T-cell recognizable p53 hotspot mutations offer opportunities for immunotherapy and immune monitoring. Recognition of p53 mutations by peripheral blood CD8 and CD4 T lymphocytes has been revealed.

Indexed as

Antigens, NeoplasmTumor Suppressor Protein p53CD4-Positive T-LymphocytesHumansImmunotherapyReceptors, Antigen, T-CellAntigens, NeoplasmReceptors, Antigen, T-CellTumor Suppressor Protein p53

Identifiers

PMID32001482
OpenAlexW3004005990

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.